Incyte Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.2%projected annual EPS growth
Analyst Coverage
23analysts covering
FY Revenue (est.)
$5.9Bnext fiscal year
FY EPS (est.)
$3.56next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 30 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Jakafi Net Product Revenue Quarterly758MTarget: 3220000000 to 3270000000
Opzelura Net Product Revenue Quarterly143MTarget: 750000000 to 790000000
Total Net Product Revenue Quarterly1.1BTarget: 4770000000 to 4940000000
Watch Items
- Jakafi Patent Expiration (Patent Cliff)Trigger: Late 2028 Exclusivity LossAction: Monitor pipeline diversification, specifically the scaling of Opzelura, Niktimvo, and the development of Jakafi XR.
- Povorcitinib Regulatory ApprovalsTrigger: Late 2026 EU / Q1 2027 US Decisions in Hidradenitis SuppurativaAction: Track FDA and EMA regulatory decisions and subsequent commercial launch metrics.
- Opzelura Medicaid Rebate DisputeTrigger: Medicaid Line Extension Treatment DeterminationAction: Monitor legal and regulatory outcomes regarding the $245.9 million accrued liability.
Research as of 2 Sep 2026